Ocugen Stock Crashes: What Should Investors Do Now? However, I wont be around to find out. However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of insight into the U.S. regulatory pathway or commercial strategy, Ramakanth stays on the sidelines for now. The broad point here is that, even with a ~$30 million market capitalization (based on updated share count information disclosed in an 8-K filing on Dec. 9), this is a company with a legitimate opportunity. MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. Can you feel the ground moving beneath your feet? Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. 86% of retail CFD accounts lose money, Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023, Ocugen upgraded at Chardan citing attractive entry point ahead of catalysts, Analysts Are Bullish on These Healthcare Stocks: Theratechnologies (THTX), Ocugen (OCGN), Ocugen (OCGN) Gets a Buy from H.C. Wainwright, Mizuho Securities Sticks to Their Buy Rating for Ocugen (OCGN), Ocugen (OCGN) Q4 2022 Earnings Call Transcript, Why Catalyst Biosciences Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket, Registration on or use of this site constitutes acceptance of our. As of this writing, Matt did not hold a position in any of theaforementioned securities. That said, for investors who understand the potential downside, there is an intriguing story here. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. Ocugen completes $100M stock sale as it works with Bharat Biotech on Its all about choice. CFO Sanjay Subramanian said that there was "the potential for near-term revenue," depending on the EUA. Custom BMW #youtube #moto #motorcycle #bike #youtubeshorts #shorts See disclosure here. UPDATE 1-Soccer-Traore on target as Wolves stun wasteful Spurs, Peruvian communities to resume blockade of crucial "mining corridor", One student loan forgiveness effort 'hasnt gotten the attention it deserves': expert, RPT-Death toll in strike on Ukraine's Zaporizhzhia rises to 11 - officials, Soccer-Traore on target as Wolves stun wasteful Spurs. Ocugen came to the market via what was essentially a reverse merger with Histogenics Corporation, a deal that closed at the end of September. In other words, it means that even by biotech standards OCGN stock is an enormously risky play. Those reverse splits generally are poorly received by the market, even if in theory they should have little to no practical impact on trading. Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). Honestly, OCGN stock is unlikely to survive. The vaccine reportedly has a 78% efficacy rate against COVID-19, significantly lower than leading vaccines granted FDA emergency authorization. For most of its history, what we now know as Ocugen stock was Histogenics, a cell therapy company focused on orthopedics. However, an EUA in India doesn't mean that Covaxin is a slam dunk to win EUA in the U.S., as well. The steep decline came after the company announced that the U.S. Food and Drug Administration (FDA) won't grant Emergency Use Authorization (EUA) for COVID-19 vaccine Covaxin in children ages two to 18. Investors need to understand the risk profile here. Healthy companies do not undergo 1-for-60 reverse stock splits like this one did in September 2019. Concerns about the delta variant, the potential need for annual booster shots and the possibility of expanding the vaccines to children have investors hopeful that Covaxin will still eventually be a huge payoff for Ocugen. The statistics support having long-term exposure to this asset class. 1125 N. Charles St, Baltimore, MD 21201. On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. Here are three prudent steps to take. The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. The average Ocugen stock price for the last 52 weeks is 2.10. That's right -- they think these 10 stocks are even better buys. Type a symbol or company name. Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. I will concede this: The one great thing about the stock market is there is a style for everyone. Investing is always a game of balancing risk and reward. While it feels cool to buy a thousand shares of OCGN stock vs. a few shares of Amazon (NASDAQ:AMZN), save yourself the heartache. Create your Watchlist to save your favorite quotes on Nasdaq.com. I will just say this on Ocugen: Theres a reason it trades for sub-$1 after hitting resistance near $180 in 2018. Keith Speights owns shares of Pfizer. Keith Speights for This requires no immediate effort on your part. But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. (See OCGN stock analysis on TipRanks). Ocugen sold $25 million of stock in a private placement before the merger. Lorem ipsum dolor sit amet, consectetur adipiscing elit. The Nasdaq has been even more impressive, rallying 67.7% in the same time frame and hitting new all-time highs in the process. OCGN - Ocugen Inc Forecast - CNNMoney.com - CNN Business 1125 N. Charles St, Baltimore, MD 21201. Nano-cap biotech play Ocugen has an intriguing story and a ton of risk. To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. If you missed that action, you missed all the gains. Please check your download folder. Hence, instead of ruining just two lives, this new Ocugen may be destroying the investment future of all who buy. Not an offer or recommendation by Stocktwits. If it goes down, your loss won't be as great as it would be if you held onto all of your shares. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. Investors should definitely reevaluate Ocugen's prospects in light of the company's bad news announced last week. Under the terms of the agreement, Ocugen is entitled to 45% of the profits from the commercialization of Covaxin in the U.S. and Canada. The CanSinoBio partnership does help, but Ocugen still has a long way to go with OCU300. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. Ocugen Inc. Announces Closing of $100 Million Registered Article printed from InvestorPlace Media, https://investorplace.com/2019/12/no-pathway-forward-for-ocugen-stock/. This can prove to be a costly lesson to learn. Why Ocugen Stock Is Crashing Today By Keith Speights - Mar 4, 2022 at 11:42AM Key Points The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Create your Watchlist to save your favorite quotes on Nasdaq.com. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Ocugen abandoned its pursuit of a U.S. EUA for Covaxin in immunizing adults last year. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days later. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. An unprofitable biotech that focused on commercializing therapies to cure blindness prior to the present pandemic, Ocugen ( OCGN) stock took on a new life on December 22, when it announced. Nasdaq Biotech companies have emerged from similar levels to become huge winners, as evidenced simply by looking at some of the best biotech stocks for 2019. This is most likely a result of the stocks meteoric rise and analysts inability to turnaround new price targets so quickly. But if they do, Ocugen stock at the least looks like an intriguing bet. That doesnt mean success is guaranteed. Add in a $31 million market capitalization and potentially significant cash burn, and Ocugen stock self-evidently is not for risk-averse investors. Shares declined 85% in three sessions around the closing of the merger, which also included a 1-for-60 reverse stock split. Keith Speights has no position in any of the stocks mentioned. Is Ocugen Stock Still Worth Buying After Its 800%-Plus Rally? Analyst Histogenics itself highlights the risks involved in small-cap biotech. 1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell, 3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street, 2 Reasons to Avoid a Roth 401(k) for Your Retirement Savings, Warren Buffett's Latest $2.9 Billion Buy Brings His Total Investment in This Stock to $66 Billion in 4 Years, Want $1 Million in Retirement? The Motley Fool has a disclosure policy. *ALL INFO ABOUT THE BIKE AND GEAR USED DOWN BELOW**If not listed it's left stock*BIKE: 2018, BMW R NINET SCRAMBLER.EXHAUST: Akrapovic Headers, Uni. Even before that point, the most promising candidates generally can find funding. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Do not expect a recovery in Ocugen stock. At the time, Ocugen was left for dead. The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. To be sure, current cash isnt enough. If OCU300 is approved, theres a reasonably large market. Ocugen: Peripheral Scandals Taint This Expired COVID-19 'Me-Too' Longshot Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. Copyright 2023 InvestorPlace Media, LLC. The agreement stipulates Ocugen will hold the vaccines U.S. rights, and the remaining details are expected to be finalized over the coming weeks. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. Cassava Sciences (NASDAQ:SAVA) has soared 454% in just the last three months. Remember, though, that Moderna achieved this while working closely with the U.S. government (including receiving funding from Uncle Sam) and during a period when vaccines weren't widely available. It means that raising capital will be more difficult going forward. There Are So Many Stocks to Buy Ocugen Isn't One of Them More importantly, the 5-star analyst added, COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum," which, the analyst believes," bodes well for the success of the ongoing Phase 3 trial in India.. You canfollow Will on Twitterat @HealyWriting. How can we possibly evaluate a stock on a fundamental basis with that being reality? Emergency Use . Even though Ocugen did raise $25 million in a private placement, the story behind OCU300 clearly was not enough to support an initial public offering on its own. Its certainly possible the deal will fall through, leaving Ocugen with just the $15.8 million in cash with which it closed the third quarter, according to its 10-Q. Ocugen does have at least 180 days to cure that problem, but the simplest answer is for the company to execute a reverse stock split. For investors new to the story, there are some positives when it comes to OCGN stock. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. Why Ocugen Stock Is Crushing It Today | Nasdaq Learn More. Maybe OCGN stock will be one of them again. *Stock Advisor returns as of June 7, 2021. However, even from this limited vantage point, OCGN appears destined to fail. Start trading Options with Saxo today. Making the world smarter, happier, and richer. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. Written by With no effective treatments, and without a clear reason to exist, I would avoid buying Ocugen stock even as a speculative play. It has real management. Theres even room for more lines. OCGN | Ocugen Inc. Stock Price & News - WSJ The reverse merger that brought Ocugen to the public markets led to huge losses but some investors are buying the dip. Unfortunately, both the merger and the reverse split have failed to stem the decline of former Histogenics stock. It's hard to say for sure. Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. Theres even room for more lines. Pricing likely would be favorable, given the lack of alternative treatments. This decision isn't surprising, considering that Ocugen previously abandoned the pursuit of an EUA path for the vaccine in adults. The equity has experienced a continual decline for years. Source: Chart courtesy of StockCharts.com. You could sell some or all of your Ocugen shares and buy long-term call options on the stock. Cost basis and return based on previous market day close. Unfortunately for longs, OCGN is much closer to the worst of conditions. Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. Theres an opportunity here. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Ocugen - Stock Price History | OCGN | MacroTrends Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXINs development. Names like Ocugen (NASDAQ:OCGN) arent trading for about 50 cents apiece by accident. InvestorPlace - Stock Market News, Stock Advice & Trading Tips. The content is intended to be used for informational purposes only. Ocugen to Present at the 2018 BIO International Convention | Ocugen, Inc. ET on Friday. Guys, theres no revenue here! In December, Ocugen stated that it had put together an advisory board of "leading academic and industry experts to evaluate the clinical and regulatory path to approval in the U.S. market." Copy and paste multiple symbols separated by spaces. The short answer is: everything. The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. Investors who have owned stocks in the last year have generally experienced some big gains. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market. In November, Bharat Biotech began Phase 3 testing of Covaxin in India. Ocugen. Part of the proceeds will be used to support its partnership with Bharat. A partnership with a respected Asian biotechnology company offers some validation to the pipeline, and a key product is progressing through Phase III trials. All rights reserved. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. Its worth emphasizing: Ocugen stock is a play with enormous risk. All rights reserved. The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell Amryt Pharma releases Q-2 how to setup copy trading labrador gold stock that show strong revenue growth as The first split for NKE took place on October 08, Below, we'll pit these two dominant consumer-discretionary giants against each other, with an eye toward long-term . The Motley Fool recommends Moderna Inc. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. 7 Travel Stocks to Buy Banking On Pent-Up Demand. Moreover, Histogenics existed to treat orthopedic conditions, while Ocugen focused on rare eye diseases. OCGN Stock Price | Ocugen Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch Lorem ipsum dolor sit amet, consectetur adipiscing elit. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Nasdaq Ramakanth believes the broad immunity targeting different components of the virus could potentially provide better protection against emerging mutant viruses, such as the one currently circulating in the UK. With this in mind, in the Phase 1 study, COVAXIN has shown robust antibody responses against spike (S1) protein, receptor-binding domain (RBD) and the nucleocapsid (N) protein of SARS-CoV-2. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. But there is no question some big-name stocks performed better than others along the way. Nor should one look forward to OCGN stock to becoming the next GW Pharmaceuticals (NASDAQ:GWPH) or Cara Therapeutics (NASDAQ:CARA). The latest closing stock price for Ocugen as of March 03, 2023 is. Ocugen hasn't stated yet when a potential late-stage study of Covaxin could start. Other than an emphasis on cell therapies, the companies had almost nothing in common. Ill be sticking to the stocks that are actually working. There's still a chance that the vaccine could receive a green light in Canada. Do Not Sell My Personal Information (CA Residents Only). The company initiated its Phase 3 trial of OCU300 back in July 2018. Almost all the headlines about Ocugen in the past year have been about the companys COVID-19 vaccine candidate. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days. That's not going to happen now.
Secrets Of Sulphur Springs Spoilers, Do Steve And Catherine Get Married, Fiches Exercices Taoki Cp, Articles O